Gland Pharma Limited (GLAND) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹3,285 (+4.86% day change)
Key ratios
- P/E ratio
- 52.69
- P/B ratio
- 2.7
- ROE (%)
- 9.92
- ROCE (%)
- 11.06
- Debt/Equity
- 0.03
- Dividend yield (%)
- 1.06
- Market cap (₹ Cr)
- 54,206.07
Forensic checks
Piotroski F-Score: 9/9 · Altman Z-Score: 12.05 · Beneish M-Score: -2.45
InvestSights quality score
73.6/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Consolidated revenue growth: guided 15%, delivered 14.5% (FY26) — missed guidance
- Base business adjusted EBITDA margin: guided 35%, delivered 37% (Q2 FY26) — exceeded guidance
Latest earnings call (Q1 FY27)
AI summary: The central signal was the transition of Gland’s CDMO strategy from individual programmes toward large, multi-product manufacturing partnerships. The newly announced agreement covers 55 SKUs across 3 sites, has stated revenue potential of USD90 million to USD100 million, and is expected to generate revenue from calendar year 2029, with the full portfolio targeted for launch…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.